Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMXR287)

Drug Name

FR-79620 Drug Info

Synonyms

3-(5-methyl-2-phenyl-1H-imidazol-4-yl)pyridine

Indication

Disease Entry	ICD 11	Status	REF
Diabetic complication	5A2Y	Preclinical	[1]
Eating disorder	6B82	Preclinical	[1]
Obesity	5B81	Preclinical	[1]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Neuropeptide Y receptor type 5 (NPY5R)	TTY6EWA	NPY5R_HUMAN	Antagonist	[1]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Neuropeptide Y receptor type 5 (NPY5R)	DTT	NPY5R	6.192	6.174	6.582	6.385

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Diabetic complication

ICD Disease Classification

5A2Y

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Neuropeptide Y receptor type 5 (NPY5R)	DTT	NPY5R	7.49E-01	1.19E-02	0.03

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.